vs
Side-by-side financial comparison of Recon Technology, Ltd (RCON) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.
TriSalus Life Sciences, Inc. is the larger business by last-quarter revenue ($13.2M vs $12.2M, roughly 1.1× Recon Technology, Ltd). Recon Technology, Ltd runs the higher net margin — -6.8% vs -73.9%, a 67.0% gap on every dollar of revenue. On growth, Recon Technology, Ltd posted the faster year-over-year revenue change (111.0% vs 59.8%).
Recon Instruments Inc. was a Canadian technology company that produced smartglasses and wearable displays marketed by the company as "heads-up displays" for sports. Recon's products delivered live activity metrics, GPS maps, and notifications directly to the user's eye. Recon's first heads-up display offering was released commercially in October 2010, roughly a year and a half before Google introduced Google Glass.
TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.
RCON vs TLSI — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.2M | $13.2M |
| Net Profit | $-832.7K | $-9.8M |
| Gross Margin | 33.5% | 86.7% |
| Operating Margin | -14.6% | -24.8% |
| Net Margin | -6.8% | -73.9% |
| Revenue YoY | 111.0% | 59.8% |
| Net Profit YoY | 70.5% | 3.5% |
| EPS (diluted) | $-0.09 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.2M | $13.2M | ||
| Q3 25 | — | $11.6M | ||
| Q2 25 | — | $11.2M | ||
| Q1 25 | — | $9.2M | ||
| Q4 24 | $5.8M | $8.3M | ||
| Q3 24 | — | $7.3M | ||
| Q2 24 | — | $7.4M | ||
| Q1 24 | — | $6.5M |
| Q4 25 | $-832.7K | $-9.8M | ||
| Q3 25 | — | $-10.8M | ||
| Q2 25 | — | $-8.3M | ||
| Q1 25 | — | $-10.4M | ||
| Q4 24 | $-2.8M | $-10.1M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $-4.3M | ||
| Q1 24 | — | $-13.2M |
| Q4 25 | 33.5% | 86.7% | ||
| Q3 25 | — | 83.5% | ||
| Q2 25 | — | 83.9% | ||
| Q1 25 | — | 83.7% | ||
| Q4 24 | 31.7% | 85.3% | ||
| Q3 24 | — | 86.3% | ||
| Q2 24 | — | 87.6% | ||
| Q1 24 | — | 85.0% |
| Q4 25 | -14.6% | -24.8% | ||
| Q3 25 | — | -77.9% | ||
| Q2 25 | — | -65.4% | ||
| Q1 25 | — | -79.9% | ||
| Q4 24 | -63.9% | -91.8% | ||
| Q3 24 | — | -118.9% | ||
| Q2 24 | — | -111.0% | ||
| Q1 24 | — | -180.8% |
| Q4 25 | -6.8% | -73.9% | ||
| Q3 25 | — | -93.5% | ||
| Q2 25 | — | -73.9% | ||
| Q1 25 | — | -113.2% | ||
| Q4 24 | -48.9% | -122.4% | ||
| Q3 24 | — | -32.6% | ||
| Q2 24 | — | -58.8% | ||
| Q1 24 | — | -204.5% |
| Q4 25 | $-0.09 | $-0.22 | ||
| Q3 25 | — | $-0.96 | ||
| Q2 25 | — | $-0.27 | ||
| Q1 25 | — | $-0.39 | ||
| Q4 24 | $-0.31 | $-0.38 | ||
| Q3 24 | — | $-0.12 | ||
| Q2 24 | — | $-0.21 | ||
| Q1 24 | — | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.7M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $66.4M | $-33.9M |
| Total Assets | $77.6M | $35.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.7M | $20.4M | ||
| Q3 25 | — | $22.7M | ||
| Q2 25 | — | $26.5M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | $19.9M | $8.5M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | — | $16.5M | ||
| Q1 24 | — | $4.0M |
| Q4 25 | $66.4M | $-33.9M | ||
| Q3 25 | — | $-26.7M | ||
| Q2 25 | — | $-19.4M | ||
| Q1 25 | — | $-34.4M | ||
| Q4 24 | $66.9M | $-25.9M | ||
| Q3 24 | — | $-20.4M | ||
| Q2 24 | — | $-25.3M | ||
| Q1 24 | — | $-36.0M |
| Q4 25 | $77.6M | $35.3M | ||
| Q3 25 | — | $36.5M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $28.6M | ||
| Q4 24 | $74.2M | $24.0M | ||
| Q3 24 | — | $27.5M | ||
| Q2 24 | — | $32.4M | ||
| Q1 24 | — | $17.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.9M | $-2.5M |
| Free Cash FlowOCF − Capex | — | $-2.5M |
| FCF MarginFCF / Revenue | — | -19.1% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-19.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.9M | $-2.5M | ||
| Q3 25 | — | $-3.7M | ||
| Q2 25 | — | $-7.3M | ||
| Q1 25 | — | $-4.5M | ||
| Q4 24 | $-1.7M | $-5.7M | ||
| Q3 24 | — | $-10.8M | ||
| Q2 24 | — | $-13.4M | ||
| Q1 24 | — | $-10.9M |
| Q4 25 | — | $-2.5M | ||
| Q3 25 | — | $-3.9M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-5.3M | ||
| Q4 24 | — | $-5.8M | ||
| Q3 24 | — | $-11.0M | ||
| Q2 24 | — | $-13.5M | ||
| Q1 24 | — | $-10.9M |
| Q4 25 | — | -19.1% | ||
| Q3 25 | — | -33.9% | ||
| Q2 25 | — | -66.1% | ||
| Q1 25 | — | -57.3% | ||
| Q4 24 | — | -69.7% | ||
| Q3 24 | — | -149.9% | ||
| Q2 24 | — | -183.1% | ||
| Q1 24 | — | -169.3% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | — | 1.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
